1402714-51-5

Basic information

• Product Name: methyl 2-(tert-butoxy)-2-((S)-4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetate
• CAS NO: 1402714-51-5
• Molecular Weight: 456.541
• Mol File: 1402714-51-5.mol

Chemical Properties

• CAS DataBase Reference: methyl 2-(tert-butoxy)-2-((S)-4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(tert-butoxy)-2-((S)-4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetate(1402714-51-5)
• EPA Substance Registry System: methyl 2-(tert-butoxy)-2-((S)-4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetate(1402714-51-5)

Safety Data

• Hazardous Substances Data: 1402714-51-5(Hazardous Substances Data)

Upstream product

• 64965-49-7 4-hydroxy-3-iodo-2-methylquinoline 
• 1033931-93-9 4-chloro-3-iodo-2-methylquinoline 
• 1402597-31-2 methyl 2-(8-bromo-5-hydroxy-2-oxo-1,2-dihydroquinolin-4-yl)acetate 
• 1402597-29-8 methyl 2-(4-chloro-2-methylquinolin-3-yl)-2-oxoacetate 
• 1402597-30-1 methyl (S)-2-(4-chloro-2-methylquinolin-3-yl)-2-hydroxyacetate 
• 607-67-0 4-hydroxy-2-methylquinoline 
• 1155270-72-6 7-bromo-2,3-dihydropyrano[4,3,2-de]quinoline 
• 1155270-71-5 7-bromo-5-chloro-2,3-dihydropyrano[4,3,2-de]quinoline 
• 1155270-69-1 8-bromo-5-hydroxy-4-(2-hydroxyethyl)quinolin-2(1H)-one 
• 15997-62-3 2,6-dioxo-3,6-dihydro-2H-pyran-4-yl acetate 
• 100367-37-1 3-amino-4-bromophenol 
• 1155270-29-3 methyl (S)-2-(tert-butoxy)-2-(4-iodo-2-methylquinolin-3-yl)acetate 
• 1354190-18-3 2,3-dihydropyrano[4,3,2-de]quinolin-7-ylboronic acid monohydrochloride 
• 98946-18-0 tert-Butyl 2,2,2-trichloroacetimidate 

Downstream Products

• 1155419-89-8 BI-224436 
• 1155419-89-8 2-(tert-butoxy)-2-((R)-4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid 

Relevant articles and documents

Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor

Abstract A practical and efficient synthesis of a complex chiral atropisomeric HIV integrase inhibitor has been accomplished. The combination of a copper-catalyzed acylation along with the implementation of the BI-DIME ligands for a ligand-controlled Suzuki cross-coupling and an unprecedented bis(trifluoromethane)sulfonamide-catalyzed tert-butylation renders the synthesis of this complex molecule robust, safe, and economical. Furthermore, the overall synthesis was conducted in an asymmetric and diastereoselective fashion with respect to the imbedded atropisomer. Atropselective: An efficient asymmetric synthesis of an atropisomeric HIV inhibitor has been accomplished. The combination of a copper-catalyzed acylation with the implementation of BI-DIME ligands for a ligand-controlled Suzuki cross-coupling and an unprecedented bis(trifluoromethane)sulfonamide-catalyzed tert-butylation renders the synthesis of this complex molecule robust, safe, and economical.

PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR

The present invention is directed to an improved process for the preparation of Compounds of Formula (I) or salts thereof which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)- 2-methylquinolin-3-yl)acetic acid or salt thereof which is useful in the treatment of HIV infection. R4 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n) and (o); and R6 and R7 are each independently selected from H, halo and (C1-6) alkyl.